data + articles · 4 listed
newest 2017spec sheet10 rows
6-APDB (6-(2-aminopropyl)-2,3-dihydrobenzofuran) is the dihydrobenzofuran analogue of 6-APB, in which the furan ring is partially saturated, and a close structural relative of the entactogen MDA. In vitro it inhibits uptake and evokes release of serotonin, norepinephrine and dopamine, favoring serotonin and norepinephrine over dopamine in a manner resembling MDMA, and it substitutes for MDMA in drug-discrimination testing while producing locomotor stimulation. Like related benzofurans it acts as a 5-HT2B receptor agonist, an activity linked to heart-valve fibrosis with repeated use. Pharmacological data remain limited, and its entactogenic effects carry the standard risks associated with serotonin-releasing agents.
- Empathy and warmth
- Mild stimulation
- Mood elevation
- Emotional openness
- Dihydrobenzofuran MDMA-like releaser favoring serotonin and norepinephrine
- Long duration tempting redosing
- Overheating (hyperthermia)
- Cardiovascular strain
- 5-HT2B-linked heart-valve concern
Mechanism
6-APDB acts as a releasing agent and at the , , and transporters, raising all three monoamines to produce entactogenic and stimulant effects, with somewhat serotonin-favoring activity. As a member of the benzofuran/dihydrobenzofuran family it is presumed to retain 5-HT2B receptor agonism; sustained 5-HT2B activation is associated with heart-valve fibrosis, so repeated use carries that cardiac concern.
receptor fingerprint
transporter (SERT)Releasing agent / reuptake inhibitor
5-HT2B receptorPresumed agonist
()Releasing agent / reuptake inhibitor
Safetyrisks and cautions, not medical advice
6-APDB carries the usual entactogen dangers; serotonin syndrome with MAOIs and other serotonergic drugs, overheating, and cardiovascular strain, and it is fairly long-lasting. Its presumed 5-HT2B agonism raises concern about heart-valve damage with repeated use. Human data is limited, so its true potency and safety margin are not well established. Not medical advice.
Subjective profileweighing the evidence above
Not a gentler alternative, just a less studied one. It carries the full entactogen tax of overheating and serotonin toxicity, the long duration pulls people into redosing, and the presumed 5-HT2B activity raises a genuine heart-valve concern with repeated use.
Resources
No suppliers are provided for compounds like this. This entry is here for reference.
Research
- 1993first citedSynthesis and pharmacological examination of benzofuran, indan, and tetralin analogues of 3,4-(…
- 2017most recentDiscriminative stimulus and locomotor effects of para-substituted and benzofuran analogs of amp…
- 1.Pharmacological profile of novel psychoactive benzofurans.
- 2.Synthesis and pharmacological examination of benzofuran, indan, and tetralin analogues of 3,4-(methylenedioxy)amphetamine.
- 3.Discriminative stimulus and locomotor effects of para-substituted and benzofuran analogs of amphetamine.
- 4.Pharmacokinetics, pharmacodynamics and toxicology of new psychoactive substances (NPS): 2C-B, 4-fluoroamphetamine and benzofurans.
4 listed here; entry last updated July 2026
Reviews
My notesprivate to this device
FAQ
How is 6-APDB different from 6-APB?
6-APDB has a partly saturated (dihydro) benzofuran ring; it is closely related and broadly similar in effect, and it is a close relative of MDA.
Does it carry the heart-valve concern?
As a benzofuran-family compound it is presumed to retain 5-HT2B agonism, which is linked to valve damage with repeated use.
Can it be combined with antidepressants?
No. Its serotonin release makes MAOIs and other serotonergic drugs a serotonin-syndrome risk.
Adverse effects
- Long duration tempting redosing
- Overheating (hyperthermia)
- Cardiovascular strain
- 5-HT2B-linked heart-valve concern